JP2005506385A - 膵臓癌を処置するための医薬 - Google Patents

膵臓癌を処置するための医薬 Download PDF

Info

Publication number
JP2005506385A
JP2005506385A JP2003538370A JP2003538370A JP2005506385A JP 2005506385 A JP2005506385 A JP 2005506385A JP 2003538370 A JP2003538370 A JP 2003538370A JP 2003538370 A JP2003538370 A JP 2003538370A JP 2005506385 A JP2005506385 A JP 2005506385A
Authority
JP
Japan
Prior art keywords
dsrna
strand
sequence
chain
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003538370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506385A5 (enExample
Inventor
マティアス オッカー，
クリストフ ヘロルド，
アンケ ガイック，
デトレフ シュッパン，
ハンス−ペーター フォルンロッヒャー，
ローラント クロイツァー，
シュテファン リンマー，
Original Assignee
リボファーマ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10160151A external-priority patent/DE10160151A1/de
Priority claimed from PCT/EP2002/000151 external-priority patent/WO2002055692A2/de
Priority claimed from DE10230996A external-priority patent/DE10230996A1/de
Application filed by リボファーマ アーゲー filed Critical リボファーマ アーゲー
Priority claimed from PCT/EP2002/011968 external-priority patent/WO2003035868A1/de
Priority claimed from PCT/EP2002/011970 external-priority patent/WO2003035870A1/de
Publication of JP2005506385A publication Critical patent/JP2005506385A/ja
Publication of JP2005506385A5 publication Critical patent/JP2005506385A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003538370A 2001-10-26 2002-10-25 膵臓癌を処置するための医薬 Withdrawn JP2005506385A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DE10155280 2001-10-26
DE10158411 2001-11-29
DE10160151A DE10160151A1 (de) 2001-01-09 2001-12-07 Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
PCT/EP2002/000151 WO2002055692A2 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
PCT/EP2002/000152 WO2002055693A2 (de) 2001-01-09 2002-01-09 Verfahren zur hemmung der expression eines zielgens
DE10230996A DE10230996A1 (de) 2001-10-26 2002-07-09 Medikament zur Behandlung eines Pankreaskarzinoms
PCT/EP2002/011968 WO2003035868A1 (de) 2001-10-26 2002-10-25 Medikament zur erhöhung der wirksamkeit eines rezeptor-vermittelt apoptose in tumorzellen auslösenden arzeimittels
PCT/EP2002/011970 WO2003035870A1 (de) 2001-10-26 2002-10-25 Medikament zur behandlung eines pankreaskarzinoms
PCT/EP2002/011971 WO2003035082A1 (de) 2001-10-26 2002-10-25 Medikament zur hemmung der expression eines zielgens

Publications (2)

Publication Number Publication Date
JP2005506385A true JP2005506385A (ja) 2005-03-03
JP2005506385A5 JP2005506385A5 (enExample) 2006-01-05

Family

ID=56290351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003538370A Withdrawn JP2005506385A (ja) 2001-10-26 2002-10-25 膵臓癌を処置するための医薬

Country Status (1)

Country Link
JP (1) JP2005506385A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071046A1 (ja) * 2009-12-07 2011-06-16 アークレイ株式会社 疾患関連遺伝子の多型検出用プローブおよびその用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071046A1 (ja) * 2009-12-07 2011-06-16 アークレイ株式会社 疾患関連遺伝子の多型検出用プローブおよびその用途
US9200326B2 (en) 2009-12-07 2015-12-01 Arkray, Inc. Probe for detecting polymorphism in disease-related gene and use of the probe

Similar Documents

Publication Publication Date Title
US20240124874A1 (en) C/EBP Alpha Short Activating RNA Compositions and Methods of Use
JP4209678B2 (ja) 標的遺伝子の発現を阻害する方法および腫瘍を治療するための医薬
Höbel et al. Polyethylenimine/small interfering RNA‐mediated knockdown of vascular endothelial growth factor in vivo exerts anti‐tumor effects synergistically with Bevacizumab
WO2003035870A1 (de) Medikament zur behandlung eines pankreaskarzinoms
JP2010159269A (ja) トランスフェクションの効率を向上させるペプチド
EP2520651A2 (en) Sirna for inhibiting c-met expression and an anti-cancer composition comprising the same
US20100203112A1 (en) Composition of cationic phospholipid nanoparticles for effective delivery of nucleic acids
US20110287547A1 (en) Nucleic acid delivery compositions and methods
DE10230996A1 (de) Medikament zur Behandlung eines Pankreaskarzinoms
WO2005095613A1 (ja) Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
CN111526894A (zh) 将chi3l1抑制剂作为有效成分的用于预防或治疗癌症的肺转移的药物组合物
JP2005506385A (ja) 膵臓癌を処置するための医薬
US11951178B2 (en) Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
JP7585166B2 (ja) 物質送達キャリア及び組成物
WO2024134199A1 (en) Chemically modified sarna compositions and methods of use
CN117821468A (zh) 肺靶向可溶性PD-L1 mRNA脂质纳米颗粒及其应用
Yin et al. Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo
JP2021512119A (ja) 肥満及び肥満関連障害の治療のための組成物及び方法
HK40070347A (en) C/ebp alpha short activating rna compositions and methods of use
JP2004173512A (ja) ＲＮＡｉによる新規治療法および治療剤
HK40018320A (en) C/ebp alpha short activating rna compositions and methods of use
HK40018320B (en) C/ebp alpha short activating rna compositions and methods of use
CN120037380A (zh) 阻断cyld在d215位的剪切在制备脓毒症治疗药物中的应用
GB2594084A (en) Medical methods and medical uses
CN1608131A (zh) 治疗胰腺癌的药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051025

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071004